The product elicited dose-dependent Anti-PCSK9 antibody titers, potent functional inhibition of the PCSK9–LDLR interaction, and sustained lipid-lowering effects, supporting its potential as a long-acting and cost-effective therapeutic alternative to monoclonal antibodies for hypercholesterolemia. The gene discussed is LDLR; the disease is Hypercholesterolemia.